[Form 4] Relmada Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. (RLMD) filed a Form 4 reporting an equity award to director Charles J. Casamento. On 06/26/2025, Casamento received a stock option to purchase 100,000 RLMD common shares at an exercise price of $0.67 per share. The option will begin vesting on 09/26/2025 in 16 equal quarterly installments and will expire on 06/26/2035. Following the grant, Casamento beneficially owns 100,000 derivative securities related to RLMD, all held directly. No non-derivative share transactions were reported in this filing.

The filing signals additional potential dilution of up to 100,000 shares but also furthers alignment between the board and shareholders by tying future compensation to equity performance. No cash transactions, sales, or other insider dealings were disclosed.

Positive

• Alignment of interests: 100,000 options grant ties director compensation to future share appreciation.
• Long vesting schedule (16 quarterly installments) encourages ongoing engagement through at least 2029.

Negative

• Potential dilution: Option grant increases outstanding share overhang by up to 100,000 shares once exercised.

Insights

Securities Analyst

TL;DR: Director awarded 100k options at $0.67; modest dilution, aligns incentives, neutral-to-slightly-positive governance signal.

The Form 4 documents a standard equity compensation grant. A 10-year option on 100,000 shares represents a small fraction of RLMD’s typical biotech share counts, so dilution risk is limited. The exercise price of $0.67 locks in a low entry point, incentivising the director to focus on long-term value creation. Because the grant is scheduled to vest quarterly over four years, it provides continuous retention leverage. As there are no accompanying share sales, the disclosure does not raise liquidity-driven red flags. Overall market impact should be limited, but the governance alignment is incrementally positive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TRAVERSA SERGIO

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES, FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.67	06/26/2025		A		800,000		09/26/2025(1)	06/26/2035	Common Stock	800,000	$0	800,000	D

Explanation of Responses:

1. The options vest in 16 equal quarterly installments commencing on September 26, 2025.

	/s/ Sergio Traversa	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RLMD report on the latest Form 4?

Director Charles J. Casamento received a stock option for 100,000 shares at an exercise price of $0.67 on 06/26/2025.

When do the RLMD options granted to Charles Casamento start vesting?

The options begin vesting on 09/26/2025 in 16 equal quarterly installments.

What is the expiration date of the newly granted RLMD stock options?

The options expire on 06/26/2035.

Did the Form 4 report any sale of RLMD shares by the director?

No. The filing only discloses an acquisition of stock options; no share sales were reported.

How many RLMD derivative securities does the director own after the transaction?

After the grant, Charles J. Casamento beneficially owns 100,000 derivative securities (stock options).